IDEX Beats Q3 Estimates; Organic Sales Rise

IDEX Corp. beat Q3 estimates with adjusted EPS of $2.03 and revenue of about $879 million, roughly a 10% year‑over‑year increase. Management tightened 2025 adjusted EPS guidance to $7.86–$7.91. Segment results were mixed: Health & Science Technologies led with +22% to $381.0 million, Fluid & Metering rose about 5% to $317.1 million, and Fire & Safety/diversified fell about 3% to $181.9 million; adjusted gross margin was ~44.5% and adjusted EBITDA about $239.8 million. Organic sales rose roughly 5% in the quarter, with acquisitions and FX contributing to top‑line growth, and the company continues a $1 billion share repurchase program, having spent $175 million year‑to‑date, as CEO Eric D. Ashleman highlighted focus on execution amid uncertain macro conditions. The stock showed intraday volatility, rising about 6% in morning trade after results but remaining behind year‑to‑date performance. Separately, IDACORP reported Q3 operating revenue of $524.4 million, operating income of $144.8 million, net income of $124.6 million and basic EPS of $2.30.